全文获取类型
收费全文 | 1210395篇 |
免费 | 76873篇 |
国内免费 | 1699篇 |
专业分类
耳鼻咽喉 | 17309篇 |
儿科学 | 39556篇 |
妇产科学 | 31748篇 |
基础医学 | 172604篇 |
口腔科学 | 33434篇 |
临床医学 | 105180篇 |
内科学 | 227906篇 |
皮肤病学 | 28225篇 |
神经病学 | 94189篇 |
特种医学 | 49757篇 |
外国民族医学 | 224篇 |
外科学 | 185574篇 |
综合类 | 22673篇 |
现状与发展 | 1篇 |
一般理论 | 299篇 |
预防医学 | 81054篇 |
眼科学 | 28073篇 |
药学 | 95806篇 |
7篇 | |
中国医学 | 3079篇 |
肿瘤学 | 72269篇 |
出版年
2021年 | 8540篇 |
2019年 | 8795篇 |
2018年 | 13631篇 |
2017年 | 10828篇 |
2016年 | 12762篇 |
2015年 | 14256篇 |
2014年 | 18347篇 |
2013年 | 26604篇 |
2012年 | 37434篇 |
2011年 | 38814篇 |
2010年 | 22807篇 |
2009年 | 20855篇 |
2008年 | 36353篇 |
2007年 | 39311篇 |
2006年 | 39883篇 |
2005年 | 38576篇 |
2004年 | 36934篇 |
2003年 | 35597篇 |
2002年 | 34411篇 |
2001年 | 64448篇 |
2000年 | 65778篇 |
1999年 | 54782篇 |
1998年 | 13625篇 |
1997年 | 11976篇 |
1996年 | 11749篇 |
1995年 | 10925篇 |
1994年 | 9893篇 |
1993年 | 9370篇 |
1992年 | 39496篇 |
1991年 | 37900篇 |
1990年 | 37332篇 |
1989年 | 35788篇 |
1988年 | 32181篇 |
1987年 | 31331篇 |
1986年 | 29432篇 |
1985年 | 27603篇 |
1984年 | 20088篇 |
1983年 | 16854篇 |
1982年 | 9349篇 |
1979年 | 18003篇 |
1978年 | 12139篇 |
1977年 | 10818篇 |
1976年 | 9397篇 |
1975年 | 10813篇 |
1974年 | 12443篇 |
1973年 | 12015篇 |
1972年 | 11509篇 |
1971年 | 10812篇 |
1970年 | 9903篇 |
1969年 | 9549篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Human colonic goblet cells. Demonstration of distinct subpopulations defined by mucin-specific monoclonal antibodies. 总被引:7,自引:2,他引:5
We studied glycoprotein content of human colonic goblet cells, using a library of monoclonal antibodies (MAbs) directed against purified human colonic mucin (HCM). Using indirect immunofluorescence (IIF), we found that 17 of 23 anti-HCM MAbs stained some or all goblet cells of normal human colonic mucosa. We observed a variety of cellular staining patterns, including (a) diffuse (homogeneous) staining of intracellular mucin, (b) speckled (inhomogeneous) staining of mucin droplets, (c) peripheral staining of intracellular droplets, (d) cytoplasmic staining of goblet cells, and (e) apical (luminal) surface staining. Staining patterns were not associated with particular HCM species. In addition to variable patterns of IIF within individual cells, anti-HCM MAbs varied in the proportion of goblet cells stained. Some MAbs stained all goblet cells, while others stained a limited number of goblet cells. Although each goblet cell contained more than one type mucin, HCM species III, and IV and V appeared to exist in mutually exclusive goblet cell populations and it was possible to define at least seven subpopulations of goblet cells in colonic mucosa by their content of various combinations of HCM species. Anti-HCM MAbs stained goblet cells from other sites within the gastrointestinal tract to a varying extent. Anti-HCM MAbs also showed extensive cross-reactivity with rodent, rabbit, and monkey colonic mucosa. However, several anti-HCM MAbs stained only human colonic mucosa. These data show that human colonic mucosa contains discrete subpopulations of goblet cells that produce distinctive combinations of specific mucin glycoprotein species. 相似文献
992.
993.
994.
995.
Secondary prevention of coronary events in coronary artery disease (CAD) patients with aspirin is generally accepted because of ease of administration, predictable safety, and proven efficacy. The use of long-term anticoagulant therapy with heparins, vitamin-K antagonists (VKAs), or thrombin inhibitors is, however, more controversial. During the last 40 years, several trials have been conducted in order to evaluate the role of anticoagulant therapy in patients with CAD as a protection against subsequent death and thrombo-embolic complications. The conducted trials are heterogeneous in many ways, concerning comparative medications, patient populations, endpoints and follow-up, which makes a standardized recommendation on the basis of these studies difficult. This review is an overview of the largest and best studies on this topic and discusses the scientific background for a possible use of VKA or an alternative anticoagulant treatment in CAD patients, looking at both the beneficial effects and the risk of bleeding. 相似文献
996.
997.
David G Hicks Brian J Yoder Sarah Short Shannon Tarr Nichole Prescott Joseph P Crowe Andrea E Dawson G Thomas Budd Steven Sizemore Muzaffer Cicek Toni K Choueiri Raymond R Tubbs Daniel Gaile Norma Nowak Mary Ann Accavitti-Loper Andra R Frost Danny R Welch Graham Casey 《Clinical cancer research》2006,12(22):6702-6708
PURPOSE: This study aims to determine the effect of loss of breast cancer metastasis suppressor 1 (BRMS1) protein expression on disease-free survival in breast cancer patients stratified by estrogen receptor (ER), progesterone receptor (PR), or HER2 status, and to determine whether loss of BRMS1 protein expression correlated with genomic copy number changes. EXPERIMENTAL DESIGN: A tissue microarray immunohistochemical analysis was done on tumors of 238 newly diagnosed breast cancer patients who underwent surgery at the Cleveland Clinic between January 1, 1995 and December 31, 1996, and a comparison was made with 5-year clinical follow-up data. Genomic copy number changes were determined by array-based comparative genomic hybridization in 47 breast cancer cases from this population and compared with BRMS1 staining. RESULTS: BRMS1 protein expression was lost in nearly 25% of cases. Patients with tumors that were PR negative (P=0.006) or HER2 positive (P=0.039) and <50 years old at diagnosis (P=0.02) were more likely to be BRMS1 negative. No overall correlation between BRMS1 staining and disease-free survival was observed. A significant correlation, however, was seen between loss of BRMS1 protein expression and reduced disease-free survival when stratified by either loss of ER (P=0.008) or PR (P=0.029) or HER2 overexpression (P=0.026). Overall, there was poor correlation between BRMS1 protein staining and copy number status. CONCLUSIONS: These data suggest a mechanistic relationship between BRMS1 expression, hormone receptor status, and HER2 growth factor. BRMS1 staining could potentially be used in patient stratification in conjunction with other prognostic markers. Further, mechanisms other than genomic deletion account for loss of BRMS1 gene expression in breast tumors. 相似文献
998.
999.
K. C. Lødrup Carlsen M. Løvik B. Granum P. Mowinckel K. H. Carlsen 《Pediatric allergy and immunology》2006,17(4):304-312
The endotoxin receptor soluble CD14 (sCD14) has been implicated in the 'hygiene hypothesis' suggesting reduced allergic sensitization with bacterial stimulation. However, the relationship between early life sCD14 and allergic diseases is conflicting. We aimed to investigate whether possible risk factors for allergic diseases were associated with sCD14 levels at 2 yr of age. In the nested case-control study of the birth cohort studies 'Environment and Childhood Asthma study in Oslo' 411 children selected with recurrent bronchial obstruction (rBO) (n=241) and no bronchial obstruction (n=170) by 2 yr were investigated with skin prick test and structured parental interview at age 2 yr. Exposure to tobacco smoke, pets and infections was recorded semi-annually by questionnaires (0-2 yr). The sCD14 was analysed from frozen, stored serum by ELISA technique. Regression analyses were performed in all subjects with complete data (n=406, 180 girls), and in girls and in boys separately. Mean sCD14 (ng/ml) was significantly higher among girls 2035 (1973-2096) vs. 1947 (1890-2004) (boys). The sCD14 was significantly reduced among girls exposed to antenatal maternal smoking and with parental asthma, after adjusting for age, parental rhino-conjunctivitis, pet keeping and childhood infections. Recurrent otitis media (OM) increased and common colds significantly decreased sCD14 levels in girls. Boys with atopic dermatitis and rBO had reduced sCD14. Pet exposure was not significantly associated with sCD14. We report novel gender-related effects of sCD14 in early life and suggest that gender, tobacco smoke exposure, age and middle ear disease in particular should be accounted for when assessing the role of sCD14 in childhood allergic diseases. 相似文献
1000.
M. E. Falagas S. K. Kasiakou D. P. Kofteridis G. Roditakis G. Samonis 《European journal of clinical microbiology & infectious diseases》2006,25(9):596-599
The prospective case series study presented here was conducted to assess the outcome of patients with infections caused by polymyxin-only-susceptible (POS) gram-negative bacteria managed with intravenous colistin. Between July 2003 and April 2005 a total of 27 patients were infected with a POS gram-negative bacterium and received intravenous colistin at a dose of 2 million international units (MIU) (160 mg or 66.7 mg colistin base) every 8 h for a mean (±SD) duration of 13.9 (±7.5) days. Nine patients had ventilator-associated pneumonia and received, in addition to the intravenous colistin therapy, 1 MIU (80 mg or 33.3 mg colistin base) aerosolized colistin every 12 h for a mean (±SD) duration of 13 (±6.5) days. The predominant pathogens were Pseudomonas aeruginosa (n=17) and Acinetobacter baumannii (n=12); in two patients both pathogens were isolated from one clinical specimen. In-hospital mortality and clinical response were 15% and 85%, respectively. Colistin-associated nephrotoxicity was observed in two of the 27 patients. POS gram-negative pathogens represent a major threat for hospitalized patients. Colistin appears to be an effective and safe treatment, even in patients with severe underlying diseases. 相似文献